安迪蘇(600299.SH):持續加強在合成生物學研究領域的合作
格隆匯5月9日丨安迪蘇(600299.SH)在互動平台表示,加速發展特種產品業務是“雙支柱”戰略的關鍵之一。公司通過在全球範圍內優化特種產品的佈局,提升特種產品供應的成本競爭能力、供應靈活性、客户響應速度及可持續發展水平。每年,公司投入大量的研發經費用於特種產品領域,通過內部創新與外部戰略合作等多種方式確保推出新的特種產品和相關服務,同時進一步開發和加強市場營銷的產品和服務。自2014年起,公司每年推出一種新產品/新服務,其中包括新酶製劑產品、腸道健康產品等。利用創新發酵技術生產的斐康單細胞產品已於今年4月成功推向市場。另外,公司持續加強在合成生物學研究領域的合作,例如與北京化工大學等高校及研究機構建立戰略合作關係,以強化安迪蘇在生物技術及動物營養產品領域的技術佈局, 促進公司與最先進技術保持關聯並抓住可能的產業化機會。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.